Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968

European Journal of Cancer

Volumn 44, Issue 9, 2008, Pages 1332-1340

  Pisano, Claudio ^a   Zuco, Valentina ^b   De Cesare, Michelandrea ^b   Benedetti, Valentina ^b   Vesci, Loredana ^a   Foderà, Rosanna ^a   Bucci, Federica ^a   Aulicino, Concetta ^a   Penco, Sergio ^a   Carminati, Paolo ^a   Zunino, Franco ^b  

^a Sigma Tau SpA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Camptothecin; DNA damage response; Senescence; Squamous cell carcinoma

Indexed keywords

BETA GALACTOSIDASE; BETA TUBULIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; HISTONE H2AX; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; PROTEIN P53; PROTEIN RPA 2; ST 1968;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CELL AGING; CONTROLLED STUDY; DNA DAMAGE; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; DNA DAMAGE; DRUG EVALUATION; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 44449098022     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.04.004     Document Type: Article

References (19)

1. Zunino F., and Pratesi G. Camptothecins in clinical development. Exp Opin Invest Drugs 13 (2004) 269-284
2. Giovanella B.C., Hinz H.R., Kozielski A.J., et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51 (1991) 3052-3055
3. Thomas C.J., Rahier N.J., and Hecht S.M. Camptothecin: current perspectives. Bioorg Med Chem 12 (2004) 1585-1604
4. De Cesare M., Pratesi G., Perego P., et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61 (2001) 7189-7195
5. De Cesare M., Beretta G.L., Tinelli S., et al. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol 73 (2007) 656-664
6. Zuco V., Zanchi C., Cassinelli G., et al. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 11 (2004) 280-289
7. Workman P., Balmain A., McNally N.J., et al. UKCCR guidelines for the welfare of animals in experimental Neoplasia. Br J Cancer 58 (1988) 109-113
8. Pratesi G., De Cesare M., Carenini N., et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenograft. Clin Cancer Res 8 (2002) 3904-3909
9. Caserini C., Pratesi G., Tortoreto M., et al. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin Cancer Res 3 (1997) 955-961
10. Schmitt C.A. Cellular senescence and cancer treatment. Biochim Biophys Acta 1775 (2007) 5-20
11. Pouyssègur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437
12. Wadkins R.M., Bearss D., Manikumar G., et al. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res 64 (2004) 6679-6683
13. Wadkins R.M., Bearss D., Manikumar G., et al. Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity. Curr Med Chem Anticancer Agents 4 (2004) 327-334
14. Murphy B.A., Cmelak A., Burkey B., et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology 15 (2001) 47-52
15. Muggia F.M., Blessing J.A., McGehee R., and Monk B.J. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol Oncol 94 (2004) 483-487
16. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., and Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61 (2001) 6669-6673
17. Vande Velde C., Cizeau J., Dubik D., et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20 (2000) 5454-5468
18. Long III H.J. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 25 (2007) 2955-2974
19. Murphy B.A. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Exp Opin Pharmacother 6 (2005) 85-92